# Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

> **NCT04991350** · PHASE4 · TERMINATED · sponsor: **Cairo University** · enrollment: 5 (actual)

## Conditions studied

- Diabetic Macular Edema
- Macular Ischemia
- Diabetic Retinopathy
- Vascular Endothelial Growth Factor Overexpression

## Interventions

- **DRUG:** Intravitreal ranibizumab
- **DRUG:** Intravitreal bevacizumab

## Key facts

- **NCT ID:** NCT04991350
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-26
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Insufficient recruitment
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04991350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04991350, "Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04991350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*